

- O-(1,1-Dimethylethyl)-N-{{2'-(methyloxy)-3-({(2,4,6-trimethylphenyl)amino}carbonyl}amino)-4-biphenyl}carbonyl}-L-threonine;
- N-{{3',5'-Difluoro-3-({(2,4,6-trimethylphenyl)amino}carbonyl}amino)-4-biphenyl}carbonyl}-O-(1,1-dimethylethyl)-L-threonine;
- (2S)-Cyclohexyl({3',5'-difluoro-3-({(2,4,6-trimethylphenyl)amino}carbonyl}amino)-2-biphenyl}carbonyl}amino)ethanoic acid;
- O-(1,1-Dimethylethyl)-N-{{4'-fluoro-3-({(2,4,6-trimethylphenyl)amino}carbonyl}amino)-4-biphenyl}carbonyl}-L-threonine;
- O-(1,1-Dimethylethyl)-N-{{3-({(2,4,6-trimethylphenyl)amino}carbonyl}amino)-4-biphenyl}carbonyl}-L-threonine;
- 1-({3-({(2,4,6-Trimethylphenyl)amino}carbonyl}amino)-4-biphenyl}carbonyl}amino)cyclooctanecarboxylic acid;
- N-{{3-({(4-Cyclopropyl-2,6-dimethylphenyl)amino}carbonyl}amino)-3'-fluoro-4-biphenyl}carbonyl}-O-(1,1-dimethylethyl)-L-threonine;
- (2S)-cyclohexyl({3-({(4-cyclopropylphenyl)amino}carbonyl}amino)-2-naphthalenyl}carbonyl}amino)ethanoic acid;
- N-{{3-({(4-cyclopropyl-2,6-dimethylphenyl)amino}carbonyl}amino)-4'-(methyloxy)-4-biphenyl}carbonyl}-O-(1,1-dimethylethyl)-L-threonine;
- 1-({5-(4-chlorophenyl)-3-({(2,4,6-trimethylphenyl)amino}carbonyl}amino)-2-thienyl}carbonyl}amino)cyclohexanecarboxylic acid; and
- 1-({5-(3,4-difluorophenyl)-3-({(2,4,6-trimethylphenyl)amino}carbonyl}amino)-2-thienyl}carbonyl}amino)cyclohexanecarboxylic acid.
- 36.** A pharmaceutical composition comprising a compound of claim 1, a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof and at least one excipient.
- 37.** A method of treating a mammal suffering from diabetes, a condition associated with diabetes, or both comprising the administration of a compound of claim 1, a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof.

38. The method of claim 37 wherein said mammal is a human.

39. A method of treating a mammal suffering from diabetes, a condition associated with diabetes, or both comprising the administration to said mammal of a pharmaceutical composition comprising a compound of claim 1, a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof and at least one excipient.

40. The method of claim 39 wherein said mammal is a human.

41. A method of treating a mammal suffering from tissue ischemia, myocardial ischemia, or both comprising the administration of a compound of claim 1, a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof.

42. The method of claim 41 wherein said mammal is a human.

43. A method of treating a mammal suffering from tissue ischemia, myocardial ischemia, or both comprising the administration to said mammal of a pharmaceutical composition of a compound of claim 1, a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof and at least one excipient.

44. The method of claim 43 wherein said mammal is a human.

45. A process of making a compound of claim 1 comprising a solid-phase synthesis using at least one isocyanate.

46. A process of making a compound of claim 1 comprising a solid-phase synthesis using at least one urea carboxylic acid.

47. A process of making a compound of claim 1 comprising a solution-phase synthesis using at least one urea carboxylic acid.

48. A process of making a compound of claim 1 comprising a solid-phase synthesis using at least one acid chloride.

49. A process of making a compound of claim 1 comprising a solution-phase synthesis using at least one isocyanate.

50. A process of making a compound of claim 1 comprising a solution-phase synthesis using at least one carboxylic acid.

51.-54. (canceled)

* * * * *